1 June 2011 in Cell Metabolism
1 August 2018 in The American Journal of Medicine
1 April 2011 in Anesthesiology
APPROXIMATELY 300,000 patients undergo cardiac surgical procedures each year in the United States. More than 80% of routine cardiac surgical procedures are performed using cardiopulmonary bypass (CPB).1 Acute kidney injury (AKI; previously referred to as acute renal failure) after CPB is a well-known, yet incompletely understood, entity that has significant implications on both short- and long-term outcomes. The development of AKI after CPB is associated with a significant increase in infectious complications, an increase in length of hospital stay, and greater mortality when compared with patients without AKI-CPB.2 The incidence of AKI-CPB averages 20–30%, depending on the definition used and the duration of the postoperative period studied.3,4 Furthermore, more patients with AKI-CPB who require dialysis remain dialysis dependant. For all patients undergoing CPB, the risk of AKI-CPB is the least in those who undergo coronary artery bypass grafting (CABG) only; the risk increases for patients undergoing valve replacement surgery; and the risk is the greatest after combined CABG-valve procedures.4 There has not been a significant reduction in mortality, despite many recent advances in our understanding of the causative pathophysiology and pharmacotherapeutics of AKI-CPB. Furthermore, advances in renal replacement therapies (RRTs) have not significantly altered the overall mortality associated with AKI-CPB.
1 April 2010 in Molecular Endocrinology
Prolonged fasting alters skeletal muscle gene expression in a manner that promotes myofiber atrophy, but the underlying mechanisms are not fully understood. Here, we examined the potential role of activating transcription factor 4 (ATF4), a transcription factor with an evolutionarily ancient role in the cellular response to starvation. In mouse skeletal muscle, fasting increases the level of ATF4 mRNA. To determine whether increased ATF4 expression was required for myofiber atrophy, we reduced ATF4 expression with an inhibitory RNA targeting ATF4 and found that it reduced myofiber atrophy during fasting. Likewise, reducing the fasting level of ATF4 mRNA with a phosphorylation-resistant form of eukaryotic initiation factor 2α decreased myofiber atrophy. To determine whether ATF4 was sufficient to reduce myofiber size, we overexpressed ATF4 and found that it reduced myofiber size in the absence of fasting. In contrast, a transcriptionally inactive ATF4 construct did not reduce myofiber size, suggesting a requirement for ATF4-mediated transcriptional regulation. To begin to determine the mechanism of ATF4-mediated myofiber atrophy, we compared the effects of fasting and ATF4 overexpression on global skeletal muscle mRNA expression. Interestingly, expression of ATF4 increased a small subset of five fasting-responsive mRNAs, including four of the 15 mRNAs most highly induced by fasting. These five mRNAs encode proteins previously implicated in growth suppression (p21Cip1/Waf1, GADD45α, and PW1/Peg3) or titin-based stress signaling [muscle LIM protein (MLP) and cardiac ankyrin repeat protein (CARP)]. Taken together, these data identify ATF4 as a novel mediator of skeletal myofiber atrophy during starvation.
1 February 2012 in Journal of Cardiothoracic and Vascular Anesthesia
16 July 2015 in Clinical Kidney Journal
The ubiquitin proteasome pathway plays a key role in cell cycle, function and survival. Bortezomib (BTZ) and Carfilzomib (CFZ) are the first two inhibitors of the proteasome pathway, indicated in treatment of patients with multiple myeloma. In the past few years, there have been few case reports that have highlighted the association between proteasome inhibitors (BTZ and CFZ) with acute kidney injury (AKI). In most of these case reports and initial trials, the underlying mechanism of AKI has been unclear. In this article, we discuss the association and pathogenesis of proteasome inhibitors-associated AKI. We also report the first case of CFZ-associated AKI with kidney biopsy evidence of thrombotic microangiopathy and the presence of microangiopathic hemolytic anemia.